Lexicon Pharmaceuticals Inc. is a Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients’ lives. The company commercializes and develops drugs and drug candidates.
Lexicon Pharmaceuticals Inc. (LXRX) had a good day on the market for Thursday December 17 as shares jumped 15.51% to close at $3.50. About 10.53 million shares traded hands on 32,532 trades for the day, compared with an average daily volume of n/a shares out of a total float of 117.47 million. After opening the trading day at $3.01, shares of Lexicon Pharmaceuticals Inc. stayed within a range of $3.57 to $2.96.
With today’s gains, Lexicon Pharmaceuticals Inc. now has a market cap of $411.16 million. Shares of Lexicon Pharmaceuticals Inc. have been trading within a range of $4.66 and $1.03 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients’ lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.
Lexicon Pharmaceuticals Inc. is based out of The Woodlands, TX and has some 184 employees. Its CEO is Lonnel Coats.